Skip to Main Content
  • Yale Cancer Center - Prostate and Urologic Cancers Program
    Smilow Cancer Hospital at Yale New Haven
    35 Park Street, Ste North Pavilion 8
    New Haven, CT 06511

Joseph Kim, MD

Medical Oncology, Hematology & Oncology
Telehealth is available
Learn more about telehealth
Patient type treated
Adult
Accepting new patients
Yes
Referral required
From patients or physicians

Biography

Dr. Joseph Kim received his medical oncology fellowship training at National Cancer Institute, NIH, where he received training in development of clinical trials of novel cancer therapies for genitourinary cancers and other solid tumors. He is also a recipient of several awards, including Young Investigator Award by Conquer Cancer Foundation, American Society of Clinical Oncology (ASCO). Dr. Kim specializes in early phase clinical trials of novel cancer therapies and in caring for patients with prostate cancer, urinary tract and bladder cancer, penile cancer, testicular cancer, and other genitourinary malignancies. Dr. Kim research interest include DNA repair pathway, mTOR pathway, tumor hypoxia, cancer immunotherapy.  Dr. Kim is currently spearheading several NCI-sponsored clinical trials of PARP inhibitor, olaparib in combination with a VEGFR tyrosine kinase inhibitor, cediranib, in prostate cancer (CTEP# 9984) and in other advanced solid tumors (CTEP #9881) as well as a mTOR inhibitor, sapanisertib (aka TAK228 or MLN0128) for advanced urinary tract cancers (CTEP #9767) as the Study Chair.  He is an active member of Society of Immunotherapy of Cancer, AACR and ASCO. 

Titles

  • Associate Professor of Internal Medicine (Medical Oncology)

Education & Training

  • Fellow
    National Institutes of Health (2013)
  • Resident
    Emory University School of Medicine (2010)
  • MD
    Wake Forest University School of Medicine (2007)

Languages Spoken

  • English
  • 한국어 (Korean)

Additional Information

Biography

Dr. Joseph Kim received his medical oncology fellowship training at National Cancer Institute, NIH, where he received training in development of clinical trials of novel cancer therapies for genitourinary cancers and other solid tumors. He is also a recipient of several awards, including Young Investigator Award by Conquer Cancer Foundation, American Society of Clinical Oncology (ASCO). Dr. Kim specializes in early phase clinical trials of novel cancer therapies and in caring for patients with prostate cancer, urinary tract and bladder cancer, penile cancer, testicular cancer, and other genitourinary malignancies. Dr. Kim research interest include DNA repair pathway, mTOR pathway, tumor hypoxia, cancer immunotherapy.  Dr. Kim is currently spearheading several NCI-sponsored clinical trials of PARP inhibitor, olaparib in combination with a VEGFR tyrosine kinase inhibitor, cediranib, in prostate cancer (CTEP# 9984) and in other advanced solid tumors (CTEP #9881) as well as a mTOR inhibitor, sapanisertib (aka TAK228 or MLN0128) for advanced urinary tract cancers (CTEP #9767) as the Study Chair.  He is an active member of Society of Immunotherapy of Cancer, AACR and ASCO. 

Titles

  • Associate Professor of Internal Medicine (Medical Oncology)

Education & Training

  • Fellow
    National Institutes of Health (2013)
  • Resident
    Emory University School of Medicine (2010)
  • MD
    Wake Forest University School of Medicine (2007)

Languages Spoken

  • English
  • 한국어 (Korean)

Additional Information

  • Yale Cancer Center - Prostate and Urologic Cancers Program
    Smilow Cancer Hospital at Yale New Haven
    35 Park Street, Ste North Pavilion 8
    New Haven, CT 06511